echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Qilu Pharmaceutical has introduced a "first-in-class" antibody pair...

    Qilu Pharmaceutical has introduced a "first-in-class" antibody pair...

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Guanlan Pharmaceutical

    On April 16, Qilu Pharmaceutical and Peptron jointly announced that the two parties have reached an exclusive license agreement for the latter's antibody-conjugated drug (ADC) targeting MUC1.
    Qilu Pharmaceutical has obtained this drug under development worldwide.
    Exclusive authorization within.
    It is worth mentioning that this is not the first time that Qilu Pharmaceutical has introduced drugs.
    According to public information, Qilu Pharmaceutical has reached at least four companies in the past year to authorize cooperation, and introduced a number of potential "first-in-class" drug candidates.

    MUC1—an emerging target for cancer immunotherapy

    MUC1—an emerging target for cancer immunotherapy

    Qilu Pharmaceutical introduced an antibody-conjugated drug targeting MUC1 from Peptron this time.
    According to the terms of the agreement, Qilu Pharmaceutical has obtained the exclusive authorization of Peptron to develop, produce, sell and commercialize PAb001-ADC for cancer treatment worldwide.

    MUC1 is a highly glycosylated transmembrane protein that plays a vital role in the lubrication and protection of normal epithelial cells.
    It contains the extracellular N-terminal domain (MUC1-N) and C-terminal domain (MUC1-C).
    Among them, MUC1-C has an extracellular domain, a transmembrane domain, and a cytoplasmic tail, so it straddles the cell membrane.

    Studies have found that MUC1 is overexpressed in a variety of human epithelial malignancies, including breast, prostate, ovarian, pancreatic, colon, etc.
    , and is overexpressed in the malignant plasma cells of multiple myeloma.
    In these cases, cells overexpressing MUC1 lose their polarity, and MUC1 is abnormally distributed on the entire surface of cancer cells.
    Due to these characteristics of MUC1, it has become one of the emerging targets of cancer immunotherapy.

    According to Peptron's official website, PAb001-ADC is a "first-in-class" antibody conjugate drug targeting MUC1-C.
    In vitro studies have shown that the antibody can reduce the proliferation of breast cancer cells and can effectively target MUC1 in breast cancer in a xenograft mouse model.
    At present, the drug under development is in the pre-clinical research stage and is entering the new drug clinical trial application (IND) stage.

    Picture source: reference [2]

    Picture source: reference [2]

    According to the press release, the cooperation between Peptron and Qilu Pharmaceutical will accelerate the global development of PAb001-ADC, a potentially differentiated antibody conjugate drug.

    It is worth mentioning that MUC1 has become one of the emerging targets in the field of cancer immunotherapy.
    Public information shows that in addition to antibody-conjugated drugs, a variety of CAR-T therapies targeting MUC1 and cancer vaccines based on MUC1 are under study.

    At least four "license-in" authorization cooperations have been reached in one year

    At least four "license-in" authorization cooperations have been reached in one year

    The introduction of innovative drugs from outside has become one of the important ways for Qilu Pharmaceutical to expand its product pipeline.
    According to public information, Qilu Pharmaceutical has reached authorized cooperation with at least four companies in the past year to introduce innovative therapies with different mechanisms of action.
    In addition to this cooperation with Peptron, the following cooperations are also included.

    In February 2021, Qilu Pharmaceuticals obtained the exclusive right to develop and commercialize Cend's drug CEND-1 in Greater China.
    The first payment and milestone payment for this cooperation amounted to US$235 million.
    CEND-1, also known as iRGD, is a polypeptide that can bind to neuropilin.
    Neuropilin is one of the highly expressed proteins on pancreatic cancer cells.
    After it is combined with iRGD, it can mediate the endocytosis of cells and produce delivery vesicles.
    These vesicles can transfer the anti-cancer drugs used with iRGD from the blood to the inside of the tumor tissue, thereby enhancing the killing effect of the anti-cancer drugs.
    At present, Cend is planning to conduct a registered clinical trial of CEND-1 for pancreatic cancer, and will explore the combination of the drug and other therapies.

    In October 2020, Qilu Pharmaceutical obtained the exclusive rights to Quantum Genomics' drug candidate firibastat in China.
    According to reports, firibastat is a brain aminopeptidase A inhibitor (BAPAI) drug candidate.
    Firibastat product is a prodrug that delivers EC33 product in the brain.
    EC33 is a selective and specific inhibitor of aminopeptidase a, so it can prevent the production of angiotensin III in the brain.
    Due to its unique mechanism of action, fribastat represents a potential new treatment for hypertension.
    This type of therapy may interfere with the mechanisms involved in the occurrence of hypertension and blood pressure control, especially for hypertensive patients with special hormonal characteristics, which are characterized by low renin concentration and high vasopressin concentration.

    In July 2020, Qilu Pharmaceutical obtained the exclusive rights of Sesen Bio's VB4-845 (Vicineum) in Greater China.
    VB4-845 is a next-generation antibody-conjugated drug that will target the epithelial cell adhesion molecule (EpCAM) antibody fragment on the surface of tumor cells and the cytotoxic Pseudomonas exotoxin A (ETA).
    Linked together by stable genetically engineered polypeptides.
    According to reports, EpCAM is highly expressed on the surface of non-muscle-invasive bladder cancer cells, but the expression level is relatively low or not expressed in normal cells.
    The advantage of VB4-845 ADC therapy is that it has a small molecular weight, which can promote tumor penetration and drug delivery.
    Qilu Pharmaceutical has recently initiated phase 3 clinical trials of VB4-845 in China to evaluate the effectiveness and safety of VB4-845 injection in the treatment of patients with non-muscular invasive bladder cancer.

    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
    If you need guidance on treatment plans, please go to a regular hospital for treatment.

    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
    If you need guidance on treatment plans, please go to a regular hospital for treatment.

    Reference

    Reference

    [1]Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC.
    Retrieved Apr 16, 2021, from -for-anti-muc1-adc-301270464.
    html

    [1]Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC.
    Retrieved Apr 16, 2021, from -for-anti-muc1-adc-301270464.
    html

    [2] Peptron's official website.
    From

    [2] Peptron's official website.
    From [3]Cend Therapeutics and Qilu Pharmaceutical Announce Partnership.
    Retrieved Feb 16, 2021, from https://cendrx.
    com/media/#press-releases

    [3]Cend Therapeutics and Qilu Pharmaceutical Announce Partnership.
    Retrieved Feb 16, 2021, from https://cendrx.
    com/media/#press-releases

    [4]Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical.
    Retrieved Oct 29, 2020, from https://quantum-genomics.
    com/en/press-releases/?ID=ACTUS-0-65617&CLIENT=ACTUS- 0-368

    [4]Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical.
    Retrieved Oct 29, 2020, from https://quantum-genomics.
    com/en/press-releases/?ID=ACTUS-0-65617&CLIENT=ACTUS- 0-368

    [5] Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China.
    Retrieved July 31, 2020, from https://ir.
    sesenbio.
    com/news-releases/news-release- details/sesen-bio-announces-exclusive-license-agreement-qilu

    [5] Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China.
    Retrieved July 31, 2020, from https://ir.
    sesenbio.
    com/news-releases/news-release- details/sesen-bio-announces-exclusive-license-agreement-qilu

    attention [drug Mingkang Germany ] micro-channel public number

    [Medical attention Mingkang Germany ] ] micro-channel public number

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.